Standard BioTools Inc. Decrease in Unrecognized Tax Benefits is Reasonably Possible
Standard BioTools Inc. (LAB) had Decrease in Unrecognized Tax Benefits is Reasonably Possible of $800.00 thousand as of 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Notes › Income Taxes
us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible · last filed 2021-11-09
- 2021-09-30: Decrease in Unrecognized Tax Benefits is Reasonably Possible $800.00K.
- 2021-06-30: Decrease in Unrecognized Tax Benefits is Reasonably Possible $800.00K.
| Period end | Decrease in Unrecognized Tax Benefits is Reasonably Possible |
|---|---|
| 2021-09-30 | $800.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $800.00K 10-Q · filed 2021-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |